Perspectives on uncritical NYT coverage of cardiac mitochondrial transplant trial

One of the reasons I?m a scientist is that I find biology fascinating and admittedly novel biomedical science can really catch my eye, but more recently as a somewhat grizzled researcher, I?ve become increasingly skeptical about some ?sexy? research and [...]

https://ipscell.com/2018/07/perspectives-on-uncritical-nyt-coverage-of-cardiac-mitochondrial-transplant-trial/

Read More

TORC1 inhibition enhances immune function and reduces infections in the elderly – results from a Phase 2a randomized, placebo-controlled clinical trial.

Aging may be regulated by a discrete set of intracellular proteins including the mechanistic target of rapamycin (mTOR) kinase. mTOR functions within two multiprotein complexes called TORC1 and TORC2. Inhibition of TORC1 has extended life span in every species studied to date and ameliorated multiple aging-related pathologies including declining immune function. Mannick et al . now show that low-dose TORC1 inhibitor therapy in elderly humans decreased the incidence of all infections, improved influenza vaccination responses, and up-regulated antiviral immunity. Thus, targeting the TORC1 pathway that regulates aging may have clinical benefits for elderly humans including improvement in immune function and decreased infection rates.

http://stm.sciencemag.org/content/10/449/eaaq1564.full

Read More